EGFR and colorectal carcinoma: Approximately 40–50% of CRC presents resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy, and only 5–10% of metastatic CRC shows a positive response to anti-PD-1/PD-L1 (anti-programmed death-1/programmed cell death ligand 1) therapy [35,36].